Vimarsana
Biggest News Aggregation in the World

Page 9 - Intersect Ent Inc News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Intersect Ent Inc. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Intersect Ent Inc Today - Breaking & Trending Today

(XENT Alert) Johnson Fistel Investigates Proposed Sale of Intersect ENT; Is $28.25 a Fair Price? - Vimarsana News

(XENT Alert) Johnson Fistel Investigates Proposed Sale of Intersect ENT; Is $28.25 a Fair Price?

/PRNewswire/ -- Shareholder rights law firm Johnson Fistel, LLP has launched an investigation into whether the board members of Intersect ENT, Inc. (NASDAQ:...

Intersect ENT, Inc.: Intersect ENT Receives CE Mark Approval for PROPEL Contour for Patients with Chronic Rhinosinusitis Following Frontal Sinus Surgery - Vimarsana News

Intersect ENT, Inc.: Intersect ENT Receives CE Mark Approval for PROPEL Contour for Patients with Chronic Rhinosinusitis Following Frontal Sinus Surgery

Localized steroid-releasing sinus implant designed to maintain sinus opening now available in select EU countries Intersect ENT, Inc. (Nasdaq: XENT), a global ear, nose and throat ("ENT") medical

Glucocorticoid Agonist Market Size Key Opportunity, Application And Forecast To 2028 By Major indust - Vimarsana News

Glucocorticoid Agonist Market Size Key Opportunity, Application And Forecast To 2028 By Major indust

Search jobs 27-Apr-2021 Glucocorticoid Agonist Market Size Key Opportunity, Application And Forecast To 2028 By Major industry Players: GlaxoSmithKline plc., Teva Pharmaceutical Industries Ltd., Pfizer Inc., Vintage Labs., Jubilant Cadista Data Bridge Market Research announces the addition of new research analysis to the wide international database Glucocorticoid Agonist Market to offer insightful views over the forecast period of 2020 – 2027. This Glucocorticoid Agonist report provides an in-depth analysis of the product pipeline and developer...

Intersect ENT Announces Changes to its Board of Directors - Vimarsana News

Intersect ENT Announces Changes to its Board of Directors

Intersect ENT Announces Changes to its Board of Directors Search jobs - Resignation of Anthony Vernon and Appointment of Elisabeth Sandoval-Little - MENLO PARK, Calif.--(BUSINESS WIRE)--Intersect ENT, Inc. (Nasdaq: XENT), a global ear, nose and throat (“ENT”) medical technology leader dedicated to transforming patient care, today announced that Anthony Vernon has resigned from the Intersect ENT Board of Directors on March 31, 2021. Mr. Vernon has served on the Intersect ENT Board since 2015 and is resigning to pursue other interests. Subsequent to Mr. Vernon’s resignation, the Interse...

Growth Opportunities in the United States Drug Eluting Sinus Stent Market to 2025, Featuring Intersect ENT, Inc., Johnson & Johnson, Medtronic plc and Stryker Corporation - Vimarsana News

Growth Opportunities in the United States Drug Eluting Sinus Stent Market to 2025, Featuring Intersect ENT, Inc., Johnson & Johnson, Medtronic plc and Stryker Corporation

Share this article Share this article ResearchAndMarkets.com's offering. The US drug eluting sinus stent (DESS) market has increased significantly during the years 2018-2020, and projections are made that the market would rise in the next four years i.e. 2021-2025 tremendously. The drug eluting sinus stent (DESS) market is expected to increase due to surging healthcare expenditure, increasing prevalence of sinus related disorders, growing treatment in physician's office, limitations of FESS, favorable government initiatives for promoting the use of sinus stents, etc. Yet the market faces some...